Dynavax Technologies has patented alkyl chain modified 1H-imidazoquinoline compounds as Toll-like receptor-7 and -8 agonists to enhance immune responses. The patent covers methods of making pharmaceutical compositions and treating diseases in subjects by administering these compounds. GlobalData’s report on Dynavax Technologies gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Dynavax Technologies, Personalized cancer vaccines was a key innovation area identified from patents. Dynavax Technologies's grant share as of May 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
Immune response stimulation method using specific compounds
A recently granted patent (Publication Number: US11981670B2) discloses a method for stimulating an immune response in a mammalian subject by administering a pharmaceutical composition containing a specific compound (formula J) and a pharmaceutically acceptable excipient. The compound of formula J has a defined chemical structure and is crucial for inducing the desired immune response in the subject. The method aims to trigger an immune response that can potentially enhance the subject's ability to combat various diseases or infections.
Furthermore, the patent also covers a method for inducing an antigen-specific antibody response in a mammalian subject by administering a pharmaceutical composition containing the same compound of formula J and a pharmaceutically acceptable excipient. This method is designed to specifically target and activate the production of antigen-specific antibodies and/or T cell responses in the subject. The patent includes various specific claims related to the chemical structure of the compound, the administration route of the pharmaceutical composition, and the inclusion of additional antigens in the composition to further enhance the immune response. Overall, the patented methods offer a novel approach to boosting the immune system in mammalian subjects, potentially opening up new possibilities for developing effective vaccines or immunotherapies.
To know more about GlobalData’s detailed insights on Dynavax Technologies, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
